stockportfolio.pro
Ionis Pharmaceuticals, Inc. (IONS)
Healthcare · Biotechnology · NasdaqGS
Ionis Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $346.62M | $507.67M | $599.67M | $1.12B | $729.26M | $810.46M | $587.37M | $787.65M | $705.14M | $943.71M |
| Gross profit | — | — | $597.85M | $1.12B | $717.32M | $799.61M | $573.25M | $778.51M | $693.92M | $927.80M |
| Net income | $-60.40M | $346,000 | $273.74M | $278.14M | $-444.26M | $-28.60M | $-269.72M | $-366.29M | $-453.90M | $-381.39M |
| Net margin | -17.4% | 0.1% | 45.6% | 24.8% | -60.9% | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
Source: Ionis Pharmaceuticals, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Ionis Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IONS in your portfolio →
Ionis Pharmaceuticals, Inc. financial history by metric
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Ionis Pharmaceuticals, Inc. — frequently asked questions
What is Ionis Pharmaceuticals, Inc.'s revenue?
Ionis Pharmaceuticals, Inc. (IONS) reported revenue of $943.71M for fiscal year 2025, up 33.8% from the prior year, according to its SEC filings.
Is Ionis Pharmaceuticals, Inc. profitable?
No — IONS reported a net loss of $-381.39M in fiscal 2025.
What is IONS's P/E ratio?
Ionis Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ionis Pharmaceuticals, Inc. growing?
IONS's revenue grew at roughly 5.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ionis Pharmaceuticals, Inc. have?
As of fiscal year 2025, IONS carried roughly $1.80B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ionis Pharmaceuticals, Inc.'s gross margin?
IONS's gross margin was 98.3% in fiscal 2025 — gross profit of $927.80M on revenue of $943.71M.
What is Ionis Pharmaceuticals, Inc.'s market cap?
Ionis Pharmaceuticals, Inc. (IONS) has a market capitalization of about $12.20B, based on the latest data in our nightly-refreshed cache.
When does Ionis Pharmaceuticals, Inc.'s fiscal year end?
IONS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ionis Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.